Dr. Kim on the Evolution of Therapy in Metastatic HCC


Joseph Kim, MD, discusses the evolution of therapy in metastatic hepatocellular carcinoma.

Joseph Kim, MD, professor of surgery and chief, Division of Surgical Oncology, University of Kentucky Markey Cancer Center, discusses the evolution of therapy in metastatic hepatocellular carcinoma (HCC).

Patients with metastatic HCC that has spread beyond the liver or locally advanced disease for which surgery or regional therapies are not options, are eligible to receive systemic therapy, explains Kim.

In 2007, sorafenib (Nexavar) became the first approved, targeted option to show benefit in patients with metastatic HCC, Kim says. Now, other options, such as atezolizumab (Tecentriq) in combination with bevacizumab (Avastin), have demonstrated an overall survival benefit compared with sorafenib in this patient population, concludes Kim.

Related Videos
Ahmad Tarhini, MD, PhD
Allison Winter, MD
Rocio Garcia-Carbonero, MD
Andrew Ip, MD
Anthony B. El-Khoueiry, MD
Daniel King, MD, PhD
Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study
Heinz-Josef Lenz, MD, FACP
Emrullah Yilmaz, MD, PhD
Marc-Oliver Grimm, MD